TRPV2 and dilated cardiomyopathy: Iwata and colleagues first reported cardiac specific overexpression of TRPV2 and demonstrated that blockade of TRPV2 channels prevented ventricular dilation and fibrosis, ameliorated contractile dysfunction in dilated cardiomyopathy in animal models 36.